CN102488663B - 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 - Google Patents
一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 Download PDFInfo
- Publication number
- CN102488663B CN102488663B CN 201110424798 CN201110424798A CN102488663B CN 102488663 B CN102488663 B CN 102488663B CN 201110424798 CN201110424798 CN 201110424798 CN 201110424798 A CN201110424798 A CN 201110424798A CN 102488663 B CN102488663 B CN 102488663B
- Authority
- CN
- China
- Prior art keywords
- minutes
- incubated
- acetic acid
- nitrilo acetic
- acid ethylenediamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 9
- 239000000890 drug combination Substances 0.000 title claims abstract 4
- GKNAKQZZLBLSLI-UHFFFAOYSA-N 2-acetamidoacetic acid;ethane-1,2-diamine Chemical compound NCCN.CC(=O)NCC(O)=O.CC(=O)NCC(O)=O GKNAKQZZLBLSLI-UHFFFAOYSA-N 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000008215 water for injection Substances 0.000 claims abstract description 21
- 239000000843 powder Substances 0.000 claims abstract description 15
- -1 diacetyl nitrilo acetic acid ethylenediamine Chemical compound 0.000 claims description 40
- 239000003795 chemical substances by application Substances 0.000 claims description 31
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 19
- 239000000600 sorbitol Substances 0.000 claims description 19
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- 239000000047 product Substances 0.000 claims description 6
- 229910001069 Ti alloy Inorganic materials 0.000 claims description 5
- 230000008901 benefit Effects 0.000 claims description 5
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000002347 injection Methods 0.000 abstract description 6
- 239000007924 injection Substances 0.000 abstract description 6
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 abstract 2
- 208000032843 Hemorrhage Diseases 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000413 hydrolysate Substances 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000013566 Plasminogen Human genes 0.000 description 2
- 108010051456 Plasminogen Proteins 0.000 description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 108010088842 Fibrinolysin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010038727 Respiratory tract haemorrhage Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110424798 CN102488663B (zh) | 2011-12-19 | 2011-12-19 | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110424798 CN102488663B (zh) | 2011-12-19 | 2011-12-19 | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102488663A CN102488663A (zh) | 2012-06-13 |
CN102488663B true CN102488663B (zh) | 2013-08-14 |
Family
ID=46180570
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110424798 Expired - Fee Related CN102488663B (zh) | 2011-12-19 | 2011-12-19 | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102488663B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102973520B (zh) * | 2012-07-12 | 2013-12-25 | 姚云 | 一种含有二乙酰胺乙酸乙二胺化合物的药物组合物 |
CN103012187B (zh) * | 2013-01-10 | 2014-08-20 | 黄明芳 | 一种新型二乙酰氨乙酸乙二胺化合物及其药物组合物 |
CN104352450A (zh) * | 2014-10-09 | 2015-02-18 | 海南通用康力制药有限公司 | 一种注射用二乙酰氨乙酸乙二胺冻干粉及其制备方法 |
CN110772487B (zh) * | 2019-12-09 | 2021-09-21 | 湖南科伦制药有限公司 | 一种二乙酰氨乙酸乙二胺的冻干方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1454590A (zh) * | 2003-05-26 | 2003-11-12 | 王景成 | 新凝灵冻干粉针及制备方法 |
CN1541647A (zh) * | 2003-11-06 | 2004-11-03 | 武汉佑德医药科技有限公司 | 二乙酰氨乙酸乙二胺粉针制剂及其制备方法 |
CN100418518C (zh) * | 2005-05-08 | 2008-09-17 | 余世春 | 注射用二乙酰氨乙酸乙二胺制剂、制备方法及其质量控制技术 |
-
2011
- 2011-12-19 CN CN 201110424798 patent/CN102488663B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102488663A (zh) | 2012-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102488663B (zh) | 一种二乙酰氨乙酸乙二胺药物组合物及其制备方法 | |
CN101244043A (zh) | 比伐卢定冻干粉针剂及其制备方法 | |
CN101224196A (zh) | 一种盐酸氨溴索冻干粉针及其制备方法 | |
CN107693515B (zh) | 含碱化剂和艾曲泊帕的药物组合物及其用途 | |
CN103251565A (zh) | 一种注射用伏立康唑冻干粉针剂及其制备方法 | |
CN103768063B (zh) | 一种盐酸莫西沙星药物组合物及其制备方法 | |
CN102499923A (zh) | 一种药物组合物、其制备方法及用途 | |
CN110812334A (zh) | 一种注射用伏立康唑药物组合物及其制备方法 | |
CN103435496B (zh) | 一种盐酸溴己新化合物,其制备方法及其药物组合物和制剂 | |
CN106137985B (zh) | 一种稳定的棕榈酸帕利哌酮长效制剂 | |
JPWO2015099139A1 (ja) | トホグリフロジンを含有する固形製剤及びその製造方法 | |
WO2016045530A1 (zh) | 一种高复溶性及高稳定性的绿原酸冻干粉针 | |
CN102302466A (zh) | 一种可粉末直接压片的卡培他滨药用组合物及其应用 | |
CN104013629A (zh) | 头孢哌酮钠他唑巴坦钠的复方药物组合物及其制备工艺 | |
CN103980279B (zh) | 一种甲氨蝶呤化合物及注射用甲氨蝶呤 | |
CN105998024B (zh) | 一种盐酸氟桂利嗪药物组合物 | |
CN102743342B (zh) | 一种供注射用夫西地酸钠冻干组合物 | |
CN103520186B (zh) | 一种注射用脂溶性维生素的药物组合物及其制备方法 | |
CN104721154B (zh) | 注射用谷氨酸诺氟沙星冷冻干燥粉针剂药物组合物 | |
CN103432086B (zh) | 一种注射用培美曲塞二钠冻干粉针剂及其制备方法 | |
CN103830164A (zh) | 盐酸莫西沙星注射液及其制备方法 | |
CN103565747B (zh) | 一种埃索美拉唑药物组合物及其制备方法 | |
CN108261397B (zh) | 一种高含量阿莫西林可溶性粉及其制备方法 | |
CN109350602A (zh) | 一种艾乐替尼片剂组合物 | |
CN106890146A (zh) | 一种磷酸奥司他韦分散片及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120613 Assignee: Guangdong encyclopedia Pharmaceutical Co.,Ltd. Assignor: Wang Baoming Contract record no.: 2013990000708 Denomination of invention: Drug combination containing ethylenediamine diaceturate and preparing method thereof Granted publication date: 20130814 License type: Common License Record date: 20131024 Application publication date: 20120613 Assignee: Shanxi Powerdone Pharmaceutical Co., Ltd. Assignor: Wang Baoming Contract record no.: 2013990000709 Denomination of invention: Drug combination containing ethylenediamine diaceturate and preparing method thereof Granted publication date: 20130814 License type: Common License Record date: 20131024 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160121 Address after: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee after: Beijing Bobangjiayuan Medical Technology Development Co.,Ltd. Address before: Room 12, building 93, Wanda Plaza, No. 100022 Jianguo Road, Beijing, Chaoyang District, China Patentee before: Wang Baoming |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20161222 Address after: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee after: XIZANG JIURUI HEALTH Co.,Ltd. Address before: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee before: Beijing Bobangjiayuan Medical Technology Development Co.,Ltd. |
|
DD01 | Delivery of document by public notice |
Addressee: XIZANG JIURUI HEALTH Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: XIZANG JIURUI HEALTH Co.,Ltd. Document name: Notification that Application Deemed not to be Proposed |
|
DD01 | Delivery of document by public notice | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191011 Address after: Room b6268, floor 5, building 3, yard 8, Hangfeng Road, Fengtai District, Beijing 100000 Patentee after: Beijing kangruixin Pharmaceutical Research Institute Co.,Ltd. Address before: 100022 Beijing Jianguo Road No. 93, building 12, building 1901, No. Patentee before: XIZANG JIURUI HEALTH Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
DD01 | Delivery of document by public notice |
Addressee: XIZANG JIURUI HEALTH Co.,Ltd. Document name: Notification of Passing Examination on Formalities |
|
DD01 | Delivery of document by public notice | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130814 Termination date: 20201219 |
|
CF01 | Termination of patent right due to non-payment of annual fee |